Metsera (NASDAQ:MTSR) Sees Large Volume Increase - What's Next?

Key Points

• Metsera Inc. saw a significant increase in trading volume, with 1,875,334 shares traded, marking a 50% rise from the previous session.
• Analysts have reacted positively, with multiple firms raising their price targets and issuing "buy" or "overweight" ratings, positioning Metsera's consensus price target at $63.50.
• The company operates in the biopharmaceutical sector, focusing on developing innovative hormone analog peptides for treating obesity and related conditions.

Shares of Metsera Inc. (NASDAQ:MTSR - Get Free Report) saw strong trading volume on Tuesday . 1,875,334 shares traded hands during mid-day trading, an increase of 50% from the previous session's volume of 1,250,944 shares.The stock last traded at $53.11 and had previously closed at $53.58.

Analyst Upgrades and Downgrades

Several research firms have weighed in on MTSR. Guggenheim increased their target price on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. Bank of America lifted their target price on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Leerink Partners began coverage on shares of Metsera in a research note on Tuesday, September 9th. They set an "outperform" rating and a $77.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Metsera in a research note on Wednesday, September 3rd. Finally, Wells Fargo & Company began coverage on shares of Metsera in a report on Friday, June 20th. They set an "overweight" rating and a $65.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat, Metsera has an average rating of "Buy" and a consensus price target of $63.50.

Metsera Stock Down 1.1%

The firm has a fifty day simple moving average of $35.71 and a two-hundred day simple moving average of $29.35.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MTSR. Osaic Holdings Inc. lifted its holdings in shares of Metsera by 45.5% in the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company's stock valued at $27,000 after buying an additional 296 shares during the period. BNP Paribas Financial Markets grew its position in Metsera by 100.0% during the second quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company's stock valued at $46,000 after acquiring an additional 800 shares during the period. Strs Ohio purchased a new stake in shares of Metsera in the first quarter worth about $76,000. Virtus Investment Advisers LLC purchased a new stake in shares of Metsera in the second quarter worth about $77,000. Finally, KLP Kapitalforvaltning AS purchased a new position in Metsera in the second quarter valued at about $122,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.